(2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
structure -
-
CAS No:
141206-42-0
-
Formula:
C10H21NO4
-
Chemical Name:
(2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
-
Synonyms:
1-butyl-2-(hydroxylmethyl)piperidine-3,4,5-triol;1-deoxy-galactonojirimycin;1-deoxygalacto-nojirimycin;1-deoxygalactonojirimycin;AT1001 deoxyjirimycin;Galafold;GR181413A;lucerastat;migalastat;migalastat HCl;migalastat hydrochloride;N-butyldeoxygalacto-nojirimycin;N-butyldeoxygalactonojirimycin;NB-DGJ;Lucerastat;141206-42-0;N-(n-Butyl)deoxygalactonojirimycin;(2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol;UNII-GVS3YDM418;N-Butyldeoxygalactonojirimycin;GVS3YDM418;CHEMBL1086997;ACT-434964;Lucerastat [INN];N-Butyl-DGJ;Lucerastat [USAN];N-Bu-DGJ;NB-DGJ;Lucerastat [USAN:INN];Lucerastat (JAN/USAN/INN);N- Butyldeoxygalactonojirimycin;SCHEMBL6821044;N-Butyl-deoxy-galactonojirimycin;CDP-923;DTXSID60161601;N-N-Butyl Deoxygalactonojirimycin;OGT-923;WHO 9539;BDBM50312528;MFCD00269939;ZINC13719785;N-Butyl-D-galacto-1-deoxynojirimycin;DB14872;SB18742;NCGC00181326-01;HY-106392;CS-0025710;D11439;1-Butyl-2-hydroxymethyl-piperidine-3,4,5-triol;W-201205;Q27279309;(2R,3S,4R,5S)-1-(But-1-yl)-2-(hydroxymethyl)piperidine-3,4,5-triol
-
CAS No:
Description
Lucerastat is under investigation in clinical trial NCT03425539 (Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease).
(2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol Basic Attributes
219.28 g/mol
219.14705815 g/mol
GVS3YDM418
DTXSID60161601
Safety Information
|Warning|H302+H312+H332 (33.33%): Harmful if swallowed, in contact with skin or if inhaled [Warning Acute toxicity, oral; acute toxicity, dermal; acute toxicity, inhalation]|P201, P202, P261, P264, P270, P271, P280, P281, P301+P312, P302+P352, P304+P312, P304+P340, P305+P351+P338, P308+P313, P312, P321, P322, P330, P332+P313, P337+P313, P362, P363, P403+P233, P405, and P501|Aggregated GHS information provided by 3 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
(2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol Use and Manufacturing
Human drugs -> Rare disease (orphan)|Human Drugs -> EU pediatric investigation plans
Computed Properties
Molecular Weight:219.28
XLogP3:-0.6
Hydrogen Bond Donor Count:4
Hydrogen Bond Acceptor Count:5
Rotatable Bond Count:4
Exact Mass:219.14705815
Monoisotopic Mass:219.14705815
Topological Polar Surface Area:84.2
Heavy Atom Count:15
Complexity:190
Defined Atom Stereocenter Count:4
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes
Request for Quotation